-$0.40 EPS Expected for Chemomab Therapeutics Ltd. (NASDAQ:CMMB) This Quarter

Equities research analysts forecast that Chemomab Therapeutics Ltd. (NASDAQ:CMMBGet Rating) will post earnings of ($0.40) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Chemomab Therapeutics’ earnings. Chemomab Therapeutics posted earnings per share of ($0.22) in the same quarter last year, which would indicate a negative year-over-year growth rate of 81.8%. The business is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Chemomab Therapeutics will report full-year earnings of ($1.94) per share for the current financial year, with EPS estimates ranging from ($2.20) to ($1.60). For the next financial year, analysts anticipate that the firm will report earnings of ($2.26) per share, with EPS estimates ranging from ($2.31) to ($2.20). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Chemomab Therapeutics.

Chemomab Therapeutics (NASDAQ:CMMBGet Rating) last released its earnings results on Wednesday, March 9th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.04).

CMMB has been the topic of a number of analyst reports. Oppenheimer lowered their target price on shares of Chemomab Therapeutics from $30.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday, March 10th. Zacks Investment Research downgraded shares of Chemomab Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, March 14th.

In other news, Director Neil Harris Cohen bought 6,000 shares of Chemomab Therapeutics stock in a transaction that occurred on Monday, March 14th. The shares were acquired at an average price of $4.35 per share, with a total value of $26,100.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders acquired 10,750 shares of company stock valued at $45,440. Corporate insiders own 12.22% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Yahav Achim Ve Achayot Provident Funds Management Co Ltd. purchased a new position in shares of Chemomab Therapeutics in the third quarter valued at about $34,000. GSA Capital Partners LLP bought a new stake in shares of Chemomab Therapeutics in the 4th quarter worth approximately $78,000. Geode Capital Management LLC bought a new position in shares of Chemomab Therapeutics during the third quarter valued at approximately $152,000. Virtu Financial LLC bought a new stake in Chemomab Therapeutics in the fourth quarter valued at $155,000. Finally, Advisor Group Holdings Inc. purchased a new position in Chemomab Therapeutics during the 3rd quarter valued at $608,000. 28.75% of the stock is currently owned by hedge funds and other institutional investors.

Shares of CMMB traded down $0.06 during trading hours on Thursday, reaching $3.75. The stock had a trading volume of 24,575 shares, compared to its average volume of 69,050. Chemomab Therapeutics has a 12 month low of $3.25 and a 12 month high of $46.17. The company has a market capitalization of $42.77 million, a price-to-earnings ratio of -3.18 and a beta of 0.99. The firm has a 50-day simple moving average of $4.30 and a 200 day simple moving average of $6.65.

Chemomab Therapeutics Company Profile (Get Rating)

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Featured Stories

Get a free copy of the Zacks research report on Chemomab Therapeutics (CMMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.